Сравнение
Retatrutide vs. Semaglutid
Два пептида рядом — идентичность, доказательная база, правовой статус и известные нежелательные явления.
Идентичность
Категория
Метаболизм
Метаболизм
Номер CAS
2381089-83-2
910463-68-2
Молекулярная масса
4731.6 g/mol
4113.6 g/mol
Период полувыведения
144 h
165 h
Последовательность
Y-Aib-EGTFTSDYSIYLDKQAAQDFVQWLLDTGPSSGAPPPSmodifiziertes GLP-1-Analogon (31 AS) mit C18-Fettsäure-LinkerМеханизм действия
Retatrutide
Retatrutide is a 39-amino-acid peptide with agonism at three incretin/energy-balance receptors: GLP-1R (insulin secretion, satiety), GIPR (insulin sensitivity, lipid metabolism) and the glucagon receptor (energy expenditure, lipolysis). The added glucagon activation is intended to raise catabolic energy expenditure while concurrent GLP-1/GIP action compensates the hyperglycaemic effect. Albumin binding via a fatty-acid side chain enables weekly dosing.
Semaglutid
Long-acting agonist at the GLP-1 receptor. Structurally a modified glucagon-like peptide 1 whose long half-life is achieved via a fatty-acid side chain and reversible albumin binding. Acts centrally on satiety and peripherally on glucose-dependent insulin secretion and delayed gastric emptying.
Доказательная база
Наивысшая доказательность
РКИ на людях
РКИ на людях
Исследования
5
4
из них на людях
4
3
Зафиксированные эффекты
4
3
Открытые противоречия
1
1
Задокументированные нежелательные явления
2
5
Правовой статус
Полные записи
Frequently asked questions
- What is the difference between Retatrutide and Semaglutid?
- Retatrutide is classified as "Метаболизм", while Semaglutid is classified as "Метаболизм". Retatrutide: Synthetic triagonist peptide that simultaneously activates the GLP-1, GIP and glucagon receptors. Developed by Eli Lilly; in phase-3 trials for obesity (TRIUMPH programme) and type 2 diabetes. No marketing approval yet. Semaglutid: Long-acting GLP-1 receptor agonist. Approved as a medicinal product for type-2 diabetes (Ozempic, Rybelsus), chronic weight management (Wegovy) and cardiovascular risk in obesity. One of the best-studied substances on this platform — many large human RCTs. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Retatrutide or Semaglutid?
- The highest available evidence level is "РКИ на людях" for Retatrutide and "РКИ на людях" for Semaglutid. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Retatrutide and Semaglutid in Germany and the United States?
- Германия: Retatrutide — Не одобрено, Semaglutid — Рецептурный. США: Retatrutide — Не одобрено, Semaglutid — Рецептурный. These are factual summaries with source and review date on the individual pages.